Bank Julius Baer & Co. Ltd, Zurich Humanigen, Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$3.66 - $8.22 $5,490 - $12,330	-1,500 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.93 - $17.83 $23 - $71	4 Added 0.27%	1,500 $9,000
Q2 2021 Jul 23, 2021	SELL	$13.54 - $22.74 $54 - $90	-4 Reduced 0.27%	1,496 $26,000
Q1 2021 May 10, 2021	BUY	$12.91 - $23.83 $19,365 - $35,745	1,500 New	1,500 $29,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.